1/12
06:37 pm
asnd
What Ascendis Pharma (ASND)'s Phase 2 COACH Combo Data Means For Shareholders [Yahoo! Finance]
Medium
Report
What Ascendis Pharma (ASND)'s Phase 2 COACH Combo Data Means For Shareholders [Yahoo! Finance]
1/10
01:06 am
asnd
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/9
06:01 pm
asnd
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
1/9
07:18 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
1/8
04:56 pm
asnd
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) [Yahoo! Finance]
Medium
Report
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) [Yahoo! Finance]
1/8
04:01 pm
asnd
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
Low
Report
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
1/7
03:02 pm
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/7
10:58 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at TD Cowen. They now have a $325.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at TD Cowen. They now have a $325.00 price target on the stock.
1/5
09:15 am
asnd
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
08:30 am
asnd
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/21
02:13 pm
asnd
Assessing Ascendis Pharma's 2025 Valuation After Big Run and DCF Upside Potential [Yahoo! Finance]
Medium
Report
Assessing Ascendis Pharma's 2025 Valuation After Big Run and DCF Upside Potential [Yahoo! Finance]
12/15
03:25 am
asnd
Here's My Prediction For Who Could Acquire Ascendis Pharma [Seeking Alpha]
Medium
Report
Here's My Prediction For Who Could Acquire Ascendis Pharma [Seeking Alpha]
12/15
12:11 am
asnd
Assessing Ascendis Pharma (ASND)'s Valuation After a Strong 69.72% One-Year Shareholder Return [Yahoo! Finance]
Medium
Report
Assessing Ascendis Pharma (ASND)'s Valuation After a Strong 69.72% One-Year Shareholder Return [Yahoo! Finance]
12/12
03:25 pm
asnd
Ascendis Pharma gains amid takeover speculation [Seeking Alpha]
Low
Report
Ascendis Pharma gains amid takeover speculation [Seeking Alpha]
12/11
08:44 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Stifel Nicolaus from $254.00 to $256.00. They now have a "buy" rating on the stock.
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Stifel Nicolaus from $254.00 to $256.00. They now have a "buy" rating on the stock.
12/3
08:31 am
asnd
Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
Low
Report
Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
11/29
01:30 am
asnd
Ascendis Pharma (ASND): Is There More Upside in the Valuation After Recent Momentum? [Yahoo! Finance]
Low
Report
Ascendis Pharma (ASND): Is There More Upside in the Valuation After Recent Momentum? [Yahoo! Finance]
11/28
10:23 pm
asnd
How the FDA's TransCon CNP Review Delay at Ascendis Pharma (ASND) Has Changed Its Investment Story [Yahoo! Finance]
Low
Report
How the FDA's TransCon CNP Review Delay at Ascendis Pharma (ASND) Has Changed Its Investment Story [Yahoo! Finance]
11/28
05:52 pm
asnd
How Analyst Views Are Shifting the Ascendis Pharma Story After Recent Yorvipath and Pipeline Updates [Yahoo! Finance]
Low
Report
How Analyst Views Are Shifting the Ascendis Pharma Story After Recent Yorvipath and Pipeline Updates [Yahoo! Finance]
11/26
09:17 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/25
07:09 pm
asnd
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia [Yahoo! Finance]
Medium
Report
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia [Yahoo! Finance]
11/25
06:15 pm
asnd
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
Low
Report
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
11/20
06:01 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/18
09:02 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $220.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $220.00 price target on the stock.
11/18
09:00 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Wolfe Research. They set a "peer perform" rating and a $255.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Wolfe Research. They set a "peer perform" rating and a $255.00 price target on the stock.